Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9605450 | 1.00 | RAB9A (0.58) | RAB9ALMNARECQLMAPTALDH1A1 | |
| SCHEMBL8586818 | 0.86 | RAB9A (0.67) | RAB9ALMNARECQLMAPTALDH1A1 | |
| SCHEMBL8586821 | 0.86 | RAB9A (0.67) | RAB9ALMNARECQLMAPTALDH1A1 | |
| SCHEMBL18480636 | 0.80 | MAPT (0.60) | LMNAMAPTALDH1A1CYP1B1CES2 | |
| SCHEMBL28391265 | 0.80 | RAB9A (0.60) | RAB9ALMNARECQLMAPTALDH1A1 | |
| SCHEMBL4937050 | 0.78 | ALDH1A1 (0.67) | RAB9ALMNARECQLMAPTALDH1A1 | |
| SCHEMBL9798239 | 0.78 | TNFRSF1A (0.62) | RAB9ALMNAMAPTCYP1B1NPC1 | |
| SCHEMBL11877271 | 0.78 | ALDH1A1 (0.75) | RAB9ALMNAMAPTALDH1A1CYP1B1 | |
| SCHEMBL28755492 | 0.78 | CYP1B1 (0.56) | RAB9ALMNAMAPTALDH1A1CYP1B1 | |
| SCHEMBL9798236 | 0.78 | TNFRSF1A (0.62) | RAB9ALMNAMAPTCYP1B1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| WO-2008089439-A2 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1765316-A2 | METHODS AND COMPOSITIONS FOR MODULATING BAX-KU70-MEDIATED APOPTOSIS | The President and Fellows of Harvard College (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060084085-A1 | Methods and compositions for modulating Bax-mediated apoptosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2006-04-20 | — | — | US | disclosed |
| WO-2006007411-A2 | METHODS AND COMPOSITIONS FOR MODULATING BAX-MEDIATED APOPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-01-19 | — | — | WO | disclosed |
| EP-0240320-B1 | PHENYLPYRIDINE DERIVATIVES | Chisso Corporation (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4772416-A | LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1988-09-20 | — | — | US | disclosed |
| EP-0240320-A2 | Phenylpyridine derivatives | Chisso Corporation (JP) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | RAB9A 1630/4885LMNA 1692/4885RECQL 92/4885 |
| US-20060084085-A1 | Methods and compositions for modulating Bax-mediated apoptosis | BAX, BCL2, CASP3 | RAB9A 2407/4885LMNA 72/4885RECQL 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.